Download presentation
Presentation is loading. Please wait.
1
Collaborative Staging for Colon Cases
Nicole Catlett, CTR KCR Abstractor’s Training November 16-18, 2016 Welcome to Collaborative Staging for Colon Cases! You have a copy of the CS schema used for colon cases. I will review some general rules as we go through each of the data items.
2
Collaborative Staging
Discussion about collaborative staging data items: Tumor Size Extension Tumor size/Extension Eval Lymph Nodes Lymph Node Eval DX Mets Eval I will be discussing Collaborative Staging for colon cases. Collaborative staging includes… (read slide)
3
Tumor Size General Rules: Code largest primary tumor size documented.
Code primary tumor size from pathology report when patient has a resection. Code largest primary tumor size prior to neoadjuvant treatment unless tumor is more extensive after treatment. Code largest primary tumor size from radiology or endoscopy when no surgery is performed. You will need to read the General Rules for Collaborative Staging in part I, section I of the manual. There is very important information about how to collect and code your data. I am going to mention a few but make sure you read all of the instructions. For coding tumor size (read slide).
4
Tumor size Record the tumor size in millimeters
You will convert cm to mm by multiplying by 10 Tumor size is always coded in millimeters. To convert centimeters to millimeters, you will multiply the dimension by 10. Go over examples…
5
Tumor size examples Pathology report states: 3.9 cm mucinous adenocarcinoma located in the cecum. CSTS = Colonoscopy states: 6 cm tumor in the sigmoid colon suspicious for malignancy. Let’s try some examples: #1 = 039 / #2 = 060
6
Tumor size Do not code the size of a polyp, cyst or ulcer, only the size of the cancer. EXAMPLE #1: Pathology report states tubulovillous adenoma 2 cm in size. Size of invasive carcinoma: 1.1 cm CSTS = ? Answer: 011 EXAMPLE #2: Pathology report states 1.9 cm tubular adenoma with foci of adenocarcinoma. (HINT: review tumor size extension table) Answer: 990 Foci When coding tumor size, always code the size of the primary tumor, not the size of the polyp, cyst or ulcer. Let’s try some examples…
7
Tumor size Rounding rules for coding tumor size when described in fractions of millimeters. EXAMPLES: 1. Tumor 3.7 mm = 004 mm 2. Tumor 0.9 mm = ? Answer = 001 3. Tumor 5.1 mm = ? Answer = 005 NOTE: If the tumor size is a fraction of a millimeter you will round up to 1 mm, you will not round down Example: Tumor 0.3 mm = 001 mm. You can round the tumor size when it is described in fractions of millimeters. Let’s look at some examples… Who would like to try the 2nd one? Answer: 1 mm = The 3rd one? Answer: 2 mm = 005.
8
Tumor size Using “stated as” codes EXAMPLES:
Tumor stated to be “between 4 and 5 cm CSTS = 995 Tumor stated to be less than 1 cm CSTS = ? Answer: 991 There are also “stated as codes” to use when your only description of the tumor size is a physician’s statement. Here are some examples… Less than 1 cm = 991
9
Extension General Rules 1. Code the farthest tumor extension documented. 2. Code pathologic tumor extension when patient does not receive neoadjuvant treatment. 3. Code clinical tumor extension when patient does receive neoadjuvant treatment unless the tumor extension is worse after neoadjuvant treatment then you use pathologic extension. 4. Code tumor extension based on list of ambiguous terms to be used to determine involvement. General rules for coding extension (read slide); Again, these are taken from the General Instructions, Part I, Section I of CS manual. You will need to review.
10
AMBIGUOUS TERMINOLOGY
The complete list of ambiguous terminology that can be used to determine involvement are listed on page 23 of Section I, Part I of CS manual. Sometimes there may be ambiguous terminology used to describe tumor extension. There is a complete list of these terms on page 23 of Section I, Part I of the CS manual. The list includes terms that CAN be used as involvement and terms that CANNOT be used. You will need to be familiar with this list.
11
ambiguous terminology
SOME TERMS THAT CAN BE USED: - Compatible with - Consistent with - Favors - Most likely - Probable - Presumed - Suspected - Suspicious SOME TERMS NOT TO BE USED: - abuts - approaching - attached - encased/encasing - equivocal - possible - questionable - worrisome This is not a complete list of terms. I have put a copy of the complete list in your folders for reference. This can be found in CS manual, part I, section I, general instructions.
12
Extension Identifies contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs. When coding tumor extension you are documenting the depth of tumor invasion through the colon wall layers. Now lets take a look at the colon layers Identifies contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs.
13
Layers of colon wall Layers from inside out…
Lumen (interior surface of colon "tube") Mucosa Surface epithelium Lamina propria or basement membrane— dividing line between in situ and invasive lesions Muscularis mucosae Pay close attention to which layer has been invaded on the pathology report from resected specimens. (read slide)
14
Layers of colon wall (cont’d)
Submucosa—lymphatics; potential for metastases increases Muscularis propria Subserosa—sometimes called pericolic fat, subserosal fat, mesenteric or retroperitoneal fat Serosa—present on ascending, transverse, sigmoid only (also called the visceral peritoneum) SEER Training Modules, Colon Module, U. S. National Institutes of Health, National Cancer Institute, 1/13/12. < Read layers…
15
Diagram of wall layers This simple diagram is of a colon cross-section, as if you were looking at a thin slice of colon wall that has been cut through, stained, & mounted on a slide. The inside of the colon “tube” is the lumen. Waste material passes through the lumen on its way out! Tumors most often arise from the inside layer (mucosa) and grow through the wall from the mucosa, then submucosa, then muscularis propria, then subserosa, and may finally penetrate through the serosa. Cancers become more invasive as they penetrate through each level. Different stages of disease are calculated, depending upon the depth of invasion, so it is important to read the resection path report completely & carefully to determine how far down the tumor has invaded. SEER Training Modules, Colon Module , U S National Institutes of Health, National Cancer Institute. 1/13/12 <
16
CS Extension codes Lets review the CS Extension codes located in the extension table: 000 In-situ, intraepithelial, noninvasive 050 Adeno(carcinoma), noninvasive in a polyp or adenoma 100 Invasive tumor confined to mucosa, nos including intramucosal, nos (pTis) 110 Invasive tumor confined to lamina propria, including lamina propria in the stalk of a polyp
17
CS Extension codes (cont)
120 Confined to and not through muscularis mucosae, including muscularis mucosae in a polyp 130 Confined to head of polyp, NOS 140 Confined to stalk of polyp, NOS 150 Invasive tumor in polyp, NOS 160 Invades submucosa (superficial invasion), including submucosa in stalk of polyp 170 Stated as T1 with no other information Read slide…
18
ILLUSTRATION OF T1 TUMOR The original source for this material is the AJCC cancer Staging Atlas (2006) edited by Greene et al2 and published by Springer Science and Business Media, LLC,
19
CS Extension codes (cont)
200 Invasion of muscularis propria OR stated as T2 with no other information Lets see an illustration…
20
ILLUSTRATION OF T2 TUMOR The original source for this material is the AJCC cancer Staging Atlas (2006) edited by Greene et al2 and published by Springer Science and Business Media, LLC,
21
CS Extension codes (cont)
400 Extension through wall, NOS, Invasion through muscularis propria or muscularis, NOS, Subserosal tissue/(sub)serosal fat invaded, Transmural, NOS, Wall, NOS 450 Extension to: Adjacent tissue(s), NOS Connective tissue Mesenteric fat Mesentery Pericolic fat Read slide…
22
CS Extension codes (cont)
458 Extension to fat, NOS 470 Stated as T3 with no other information Read slide …
23
ILLUSTRATION OF T3 TUMOR The original source for this material is the AJCC cancer Staging Atlas (2006) edited by Greene et al2 and published by Springer Science and Business Media, LLC,
24
CS Extension codes (cont)
500 Invasion of/through serosa (mesothelium) (visceral peritoneum); Tumor penetrates to surface of visceral peritoneum (450, 458) *COMBINATION CODE* 560 Stated as T4a with no other information 565 Adherent to other organs or structures clinically with no microscopic examination OR Tumor found in adhesion(s) if microscopic examination [T4b] (Read slide); *There maybe a combination code which applies, so you must read through all of the codes to make sure that you are coding the highest code that applies.
25
ILLUSTRATION OF T4 TUMOR The original source for this material is the AJCC cancer Staging Atlas (2006) edited by Greene et al2 and published by Springer Science and Business Media, LLC, The top left picture illustrates aT4 tumor showing gross perforation of bowel through tumor. The right hand panel shows T4 tumor directly invading adjacent bowel. The bottom picture illustrates a T4a tumor with involvement of serosa (visceral peritoneum) by tumor cells.
26
CS Extension codes (cont)
570 Adherent to other organs or structures, NOS 600 Greater omentum, small intestine (*site specific) 655 Abdominal wall or retroperitoneum (excluding fat) *except sigmoid which is code Kidney or ureter *see note about sites applicable 700 Fallopian tube or Ovary or Uterus 750 Adrenal (suprarenal) gland Bladder Diaphragm, Fistula to skin Gallbladder Other segment(s) of colon/rectum via serosa Read slide… another combo code (There are a few additional codes on your table that I have not put on my slide) . Just remember to read each code and what is included to see if it applies to your case.
27
CS Extension codes (cont)
800 Kidney Liver Ureter Other contiguous extension 850 Stated as T4b with no other information 900 Stated as T4 [NOS] with no other information 950 No evidence of primary tumor 999 Unknown Extension not stated Primary tumor cannot be assessed Not documented in patient record Read slide.. Another combo code
28
CS Extension coding exercises
Coding extension examples: Your path report states “invasion of muscularis propria into the pericolic fat with extension to serosal surface”. What code would be used? CSEXT = 550 Pathology report states “invasion through the bowel wall”. What code would be used? CS EXT = 400 Let’s look at some examples… (read slide)
29
CS tumor size/extension eval
This field is used primarily to derive the staging basis for the T category in the TNM system. In most circumstances it records how the codes for the two items “CS Tumor Size” and “CS Extension” were determined, based on the diagnostic methods employed. (Read Slide)
30
CS tumor size/extension eval
Instructions for coding: Document the staging basis for the farthest extension and/or greatest tumor size. The underlying purpose of this field is to capture the staging basis for the highest T category assigned to the case. In most circumstances, this will be the staging basis for the highest Tumor Size code or Extension code as appropriate to the site. In coding colon cancer the extension code is used to derive the T category. The T category will be derived differently based on the primary site…For colon the T category is based on the extension code. The T category depends on the depth of invasion through the layers of the bowel wall.
31
Evaluation codes Clinical Code 0 (c) Physical Exam
Imaging (CT, MRI, PET) Other non-invasive methods of examining tissues Read slide
32
Scopes Diagnostic biopsies Evaluation codes Clinical code 1 (c)
Observations at surgery Diagnostic biopsies Read slide; Colonoscopy w/ BX is included in eval code 1.
33
Evaluation codes Pathologic Code 3 (p) OR Based on surgical resection
(no or unknown prior neoadjuvant treatment) OR Based on biopsy that determines the highest T or N category Read slide
34
Evaluation codes Clinical Code 5 (c) Neoadjuvant treatment received
Clinical evidence unless pathologic evidence is more extensive than clinical Read slide; You will use an eval code 5 when a patient receives neoadjuvant TX (preop) before surgery. The cancer shows response to the TX, so you will use clinical info before TX to capture the TS & Extension. The reason for this is to record the stage of the cancer before any response.
35
Evaluation codes Neoadjuvant treatment AND
Pathologic Code 6 (yp) Neoadjuvant treatment AND pathologic evidence at Surgery is more extensive than clinical evidence before treatment Neoadjuvant therapy given, pathologic evidence available, clinical evaluation prior to neoadjuvant therapy not available Read slide; You will use an eval code 6 when the cancer has progressed through TX (it is worse than before TX).
36
Evaluation codes Autopsy Code 2 (p) - Autopsy performed
- Prior knowledge of malignancy (suspected OR diagnosed) Autopsy Code 8 (a) - Malignancy diagnosed at autopsy with no prior knowledge of malignancy (unsuspected OR undiagnosed) Read slide
37
Evaluation codes Clinical Code 9 (c) Unknown - Unknown how T, N or M
determined - Defaults to clinical (c) Read slide
38
CS TS/EXT coding exercises
Example #1 You have a CT scan showing a 8.4 cm lesion located in the cecum with stranding seen in the mesenteric tissue. The patient underwent a colonoscopy that showed adenocarcinoma. A colon resection was performed showing the cancer extended through the muscularis propria into pericolic adipose tissue. What is the Tumor Size? What is the Extension Code? What is the TS/EXT eval? TS = EXT = 450 TS/EXT Eval = 3
39
CS TS/EXT coding exercises
Example #2 A patient undergoes a screening colonoscopy and a large mass was seen in the cecum which was biopsied showing adenocarcinoma. The patient then had a CT scan of abdomen & pelvis showing a mass in cecum measuring 72 mm consistent with patient’s known history of newly diagnosed colon cancer. There is associated bowel wall thickening and stranding in adjacent mesentery, suspicious for invasion. The patient refused any other workup. What is the Tumor Size ? What is the Extension code ? What is TS/EXT Eval ? Example #2 TS = 072 EXT = 450 TS/EXT eval = 0
40
Time for a break?!
41
CS Lymph Nodes This field identifies the regional lymph nodes involved with cancer at the time of diagnosis. Record the specific involved regional lymph node chain(s) farthest from the primary site. The lymph nodes may be involved by tumor either clinically or pathologically. Record the highest applicable code in the following order: pathology report, imaging, physical exam. Read slide
42
CS Lymph Nodes Pathologic information takes precedence. If there is a discrepancy between clinical information and pathologic information about the same lymph nodes, pathologic information takes precedence if no preoperative treatment was administered. It is not necessary to biopsy every lymph node in the suspicious area to disprove involvement. Example: Mesenteric lymph nodes stated as “suspicious for involvement” on CT scan. After colon resection all lymph nodes are negative. Code CS Lymph Nodes as 000, no regional lymph node involvement. Read slide
43
CS Lymph Nodes Inaccessible lymph nodes rule for regional lymph nodes. For inaccessible lymph nodes, record CS Lymph Nodes as Code 000 (None) rather than Code 999 (Unknown) when the following three conditions are met: 1. There is no mention of regional lymph node involvement in the physical examination, pretreatment diagnostic testing or surgical exploration. 2. The patient has clinically low stage (T1, T2, or localized) disease. Read slide
44
CS Lymph Nodes Note: Code 999 can and should be used in situations where there is reasonable doubt that the tumor is no longer localized and there is no documentation of involved regional lymph nodes Read slide
45
Regional Lymph nodes for colon The original source for this material is the AJCC Cancer Staging Atlas (2006) edited by Greene et al2 and published by Springer Science and Business Media, LLC, Nodes along the sigmoid arteries are considered pericolic nodes, and their involvement is classified Here is an illustration of regional LNs for colon
46
Regional Lymph Nodes Segment Regional Lymph Nodes
Cecum - Pericolic, anterior cecal, posterior cecal, ileocolic, right colic Ascending colon - Pericolic, ileocolic, right colic, middle colic Hepatic flexure - Pericolic, middle colic, right colic Transverse colon - Pericolic, middle colic Splenic flexure - Pericolic, middle colic, left colic, inferior mesenteric Descending colon - Pericolic, left colic, inferior mesenteric, sigmoid There are between 100 and 150 lymph nodes in the mesentery of the colon. Regional lymph nodes are the nodes along the colon, plus the nodes along the major arteries that supply blood to that particular colon segment.
47
Regional Lymph Nodes Segment Regional Lymph Nodes
Sigmoid colon - Pericolic, inferior mesenteric, superior rectal, superior hemorrhoidal, sigmoidal, sigmoid mesenteric Rectosigmoid - Perirectal, left colic, sigmoid mesenteric, sigmoidal, inferior mesenteric, superior rectal, superior hemorrhoidal, middle hemorrhoidal Rectum - Perirectal, sigmoid mesenteric, inferior mesenteric, lateral sacral, presacral, internal iliac, sacral promontory (Gerota's) superior hemorrhoidal, inferior hemorrhoidal Anus - Perirectal, anorectal, superficial inguinal, internal iliac, hypogastric, femoral, lateral sacral Lymph node names may also be found in the Collaborative Stage Manual & the AJCC 7th edition Staging Manual (TNM Book). Unfortunately, specifically-named lymph nodes that are removed with a colorectal surgical specimen may not be provided on the path report or the chart. In those situations, we must code them as “regional nodes”, not specific LNs.
48
CS Lymph Nodes 000 No regional LN involvement 050 TD in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues WITHOUT regional nodal metastasis Stated as N1c with no other information on regional 110 Regional lymph nodes: Colic (NOS) Epicolic (adjacent to bowel wall) Mesocolic (NOS) Paracolic/pericolic Nodule(s) or foci in pericolic fat/adjacent mesentery/mesocolic fat Read slide
49
CS Lymph Nodes 210 Regional lymph nodes, for specific colon sites 300 Mesenteric, NOS Regional lymph node(s), NOS Stated as pathologic N1 with no other information on regional lymph nodes Read slide
50
CS Lymph Nodes 800 Lymph nodes, NOS 999 Unknown; regional lymph nodes not stated Regional lymph nodes cannot be assessed Not documented in patient record Read slide
51
lymph node coding exercises
Example #1 A patient presents with abdominal distention and pain. A CT of abdomen and pelvis is performed and shows descending colon mass with regional lymph node metastasis. What code would you use for CSLN? Answer: CSLN = 300 regional lymph nodes, nos Here is an example:
52
Lymph node coding exercises
Example #2 A patient underwent a screening colonoscopy where a transverse colon cancer was identified and biopsy shows Adenocarcinoma. The patient had surgery and the path report has 15/15 positive pericolic lymph nodes. What is the code for CSLN? Answer: CSLN = 110 Another example:
53
CS Lymph Nodes eval This field is used primarily to derive the staging basis for the N category in the TNM system. It records how the code for the item “CS Lymph Nodes” was determined, based on the diagnostic methods employed and their intent. Document the farthest involved regional nodes. Select the CS Lymph Nodes Eval code that identifies the type of report or procedure from which the information about the farthest involved regional lymph nodes was obtained. Read slide
54
Evaluation codes Clinical Code 0 (c) Physical Exam
Imaging (CT, MRI, PET) Other non-invasive methods of examining tissues Read slide
55
Endoscopic exam Diagnostic biopsy Lymph Node eval codes
Clinical code 1 (c) Endoscopic exam Observations at surgery Diagnostic biopsy Read slide
56
Lymph node Eval codes Pathologic Code 3 (p) OR
Based on surgical resection (no or unknown prior neoadjuvant treatment) OR Based on biopsy that determines the highest N category Read slide
57
Lymph node Eval codes Clinical Code 5 (c)
Neoadjuvant treatment received Clinical evidence unless pathologic evidence is more extensive than clinical
58
Lymph node Eval codes Neoadjuvant treatment AND Pathologic evidence at
Pathologic Code 6 (yp) Neoadjuvant treatment AND Pathologic evidence at Surgery is more extensive than clinical evidence before treatment Neoadjuvant therapy given, pathologic evidence available, clinical evaluation prior to neoadjuvant therapy not available
59
Lymph node Eval codes Autopsy Code 2 (p) - Autopsy performed
- Prior knowledge of malignancy (suspected OR diagnosed) Autopsy Code 8 (a) - Malignancy diagnosed at autopsy with no prior knowledge of malignancy (unsuspected OR undiagnosed)
60
Lymph nodes Eval codes Clinical Code 9 (c) Unknown
- Unknown how T, N or M determined - Defaults to clinical (c) Read slide
61
Lymph node eval coding exercises
Example #1 Patient comes to ER with abdominal pain, bloating and rectal bleeding. A CT abdomen/pelvis is performed which shows colon cancer with pericolic lymph node involvement as well as liver metastasis. What is the CSLN code? Answer: 110 pericolic LNs What is the LN eval code? Answer: 0 clinical per CT Let’s try some examples:
62
Lymph node eval coding exercises
Example #2 Patient was found to have colon cancer after undergoing a screening colonoscopy. Surgery was performed. Path report says ascending colon adenocarcinoma with involvement of 10 out of 15 lymph nodes. What is the code for CSLN ? Answer: 300 regional lymph nodes, nos What is the LN eval code ? Answer: 3 pathologic Example #2
63
Regional nodes positive
Description This field records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases. Based on pathologic information only. This field is to be recorded regardless of whether the patient received preoperative treatment. Record the total number of regional lymph nodes removed and found to be positive by pathologic examination. The number of regional lymph nodes positive is cumulative from all procedures that remove lymph nodes through the completion of surgeries in the first course of treatment. Read slide
64
Regional nodes positive
Use of code 95. Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue). Use code 95 when a positive lymph node is aspirated and there are no surgically resected lymph nodes. Read slide
65
regional nodes positive
Definition of code 97. Use code 97 for any combination of positive aspirated, biopsied, sampled or dissected lymph nodes if the number of involved nodes cannot be determined on the basis of cytology or histology.
66
Regional nodes positive
Use of code 98. Code 98 may be used in several situations. a. When the assessment of lymph nodes is clinical only. b. When no lymph nodes are removed and examined. c. When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination. d. If Regional Nodes Positive is coded as 98, regional Nodes Examined is usually coded 00.
67
Regional nodes positive
Use of code 99. Use code 99 if it is unknown whether regional lymph nodes are positive. Read slide
68
Regional nodes examined
This field records the total number of regional lymph nodes that were removed and examined by the pathologist. Based on pathologic information only. This field is to be recorded regardless of whether the patient received preoperative treatment. Cumulative nodes removed and examined. Record the total number of regional lymph nodes removed and examined by the pathologist. The number of regional lymph nodes examined is cumulative from all procedures that removed lymph nodes through the completion of surgeries in the first course of treatment. Read slide
69
Regional nodes examined
Use of code 95. Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue). Definition of “sampling” (code 96). A lymph node “sampling” is removal of a limited number of lymph nodes. Other terms for removal of a limited number of nodes include lymph node biopsy, berry picking, sentinel lymph node procedure, sentinel node biopsy, selective dissection. Use code 96 when a limited number of nodes are removed but the number is unknown. 9. Definition of “dissection” (code 97). A lymph node “dissection” is removal of most or all of the nodes in the lymph node chain(s) that drain the area around the primary tumor. Other terms include lymphadenectomy, radical node dissection, lymph node stripping. Use code 97 when more than a limited number of lymph nodes are removed and the number is unknown.
70
Cs mets at dx This field identifies the distant site(s) of metastatic involvement at time of diagnosis. Use highest applicable code. Assign the highest applicable code for metastasis at diagnosis, whether the determination was clinical or pathological and whether or not the patient had any preoperative Systemic therapy. Progression of disease. Metastasis known to have developed after the extent of disease was established (also referred to as progression of disease) should not be recorded in the CS Mets at Dx field. Read slide
71
Cs mets at dx Coding 00 versus 99
Record CS Mets at Dx as Code 00 (None) if there is no clinical or pathologic evidence of distant metastases and the patient is not treated as if metastases are present or suspected. This presumes that there are no distant metastasis that would otherwise alter the treatment approach. Code 99 may be used in situations where there is reasonable doubt that the tumor is no longer localized and there is no documentation of distant metastases. Note that code 99 maps to MX in sixth edition and cM0 in seventh edition. Read slide
72
Cs mets at dx 00 No distant metastasis
08 Metastasis limited to a single distant lymph node chain: For cecum, ascending, hepatic flexure and transverse colon: Superior mesenteric lymph nodes 16 Metastasis limited to a single distant lymph node chain: For all colon sites: Common iliac Distant lymph node(s), NOS External iliac Para-aortic Retroperitoneal 18 Metastasis limited to a single distant lymph node chain, Read slide
73
Cs mets at dx 26 Metastasis limited to a single distant organ except
peritoneum 27 Stated as M1a with no other information on distant metastasis 31 Metastases to a single distant lymph node chain listed in code 08 and to a single distant lymph node chain listed in code 16 OR Multiple distant lymph node chains listed in code 16, with or without distant lymph nodes listed in code 08 33 Metastases to multiple distant lymph node chains, NOS
74
Cs mets at dx 36 Metastases to more than one distant organ except distant lymph node(s) Metastasis to peritoneum Carcinomatosis 45 (26 or 36) + any of (08, 16, 18, or 31) Metastases to distant organs plus distant nodes 48 Stated as M1b with no other information on distant metastasis Remember there is combination codes
75
Cs mets at dx 60 Distant metastasis, NOS Stated as M1 [NOS] with no other information on distant metastasis 99 Unknown; distant metastasis not stated Distant metastasis cannot be assessed Not documented in patient record Read slide
76
Cs mets at dx exercises Example #1 CT scan that shows evidence of liver metastasis. What is METS at DX code? ANSWER: 26 (single distant organ) Example #2 CT scan shows evidence of carcinomatosis. ANSWER : 36 (carcinomatosis) Some examples:
77
Cs mets EVAL This field is used primarily to derive the staging basis for the M category in the TNM system. It records how the code for the item “CS Mets at Dx” was determined based on the diagnostic methods employed. Document the highest code in CS Mets at Dx. The primary use of the CS Mets Eval field is to assign a “c” or “p” to the M category derived from the CS Mets at Dx field. Since both clinical and pathologic evidence might be available for assessing distant metastasis, the coding of the Eval field can be confusing. The goal is to assign the Eval code that indicates the best evidence used to determine the M category. Read slide
78
Cs mets EVAL Mapping of M1 subcategories. If a specific
subcategory of M1 will be derived (such as M1a), determine if there was any pathological evidence for the specific subcategory. If so, select an Eval code that will derive a “p” staging basis. If there was only clinical evidence of the subcategory disease, select an Eval code that will derive a “c” staging basis. Read slide
79
Cs mets EVAL Eval code 0 Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on physical examination, imaging examination, and/or other non- invasive clinical evidence. No microscopic examination of metastatic specimen performed or microscopic examination was negative. This will derive a clinical M. Read slide
80
Cs mets EVAL Eval code 3 Meets criteria for AJCC pathologic staging of distant metastasis: Specimen from metastatic site microscopically positive WITHOUT pre-surgical systemic treatment or radiation OR specimen from metastatic site microscopically positive, unknown if pre-surgical systemic treatment or radiation performed OR specimen from metastatic site microscopically positive prior to neoadjuvant treatment Read slide
81
Cs mets EVAL Examples: Cecum carcinoma with lung metastases on chest X-ray and positive liver biopsy. CS Mets at Dx is coded 36 (Metastases to more than one distant organ), which maps to M1b. Code CS Mets Eval as 0, which maps to the “c” staging basis because only one organ/site was microscopically proven. Sigmoid adenocarcinoma with liver metastases on ultrasound and positive peritoneal nodule biopsy. CS Mets at Dx is coded 36 (Metastasis to peritoneum). Code CS Mets Eval as 3, which maps to the “p” staging basis because although only one organ/site is microscopically confirmed, that one organ/site is the peritoneum (M1b). Here are some examples
82
quiz time
83
CS CODING EXERCISE #1 CASE #1
A patient presents with abdominal pain. A CT scan was performed that showed sigmoid colon wall thickening, no LAD identified and no evidence of distant disease. A colonoscopy was performed where a sigmoid colon mass was BX’d showing adenocarcinoma. Patient then underwent sigmoid colon resection. The path report describes a 4.6 cm adenocarcinoma invading the muscularis propria. There were 17 benign mesenteric lymph nodes examined.
84
CS CODING EXERCISE #1 Case #1 CSTS = 046 CS EXT = 200 CS TS/EXT EVAL = 3 CSLN = 000 LN EVAL = 3 LNS POSITIVE = 0 LNS EXAMINED = 17 METS AT DX = 00 METS EVAL = 0 Lets go over the codes for case #1.
85
CS CODING EXERCISE #2 Case #2 A patient has an abnormal screening colonoscopy showing an obstructing colon cancer. The patient has a CT scan performed which shows evidence of liver and lung METS. The colon cancer appears to invade the abdominal wall. There is probable mesenteric lymph node involvement noted. The patient undergoes a CT guided BX of both the lung nodule and liver mass. Pathology from both shows metastatic carcinoma from colon primary. The patient is referred to Hospice.
86
CS CODING EXERCISe #2 Case #2 CSTS = 999 CS EXT = 655 CS TS/EXT EVAL = 0 CSLN = 300 LN EVAL = 0 LNS POSITIVE = 98 LNS EXAMINED = 00 METS AT DX = 36 METS EVAL = 3 Let’s go over case #2.
87
CS CODING EXERCISe #3 Case #3 A patient presented to ER with severe rectal bleeding and pain. CT scan showed a large mass in the descending colon. The patient was taken to operating room where a laparotomy showed a large mass in the left colon directly invading the spleen. There are mesenteric LNs suspicious for involvement. The liver was palpated and there were 3 small nodules suspicious for implants. One of these nodules was biopsied and sent for frozen, which came back as metastatic signet ring adenocarcinoma consistent with colon primary. After discussion with family, decision to abort operation.
88
CS CODING EXERCISe #3 Case #3 CSTS = 999 CS EXT = 565
CS TS/EXT EVAL = 1 CSLN = 300 LN EVAL = 0 LNS POSITIVE = 98 LNS EXAMINED = 00 METS AT DX = 26 METS EVAL = 3
89
Time for Questions
90
Contact Information Nicole Catlett, CTR KCR Senior Regional Coordinator Kentucky Cancer Registry
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.